AMGN · News · 20261104N
Market Demand Trends
AMGEN INC · 2026-11-04 · Importance 43 · Surprise 32 · In source text
Amgen’s third-quarter 2026 revenue rose more than 8% to $10.37 billion, with 17 products annualizing at more than $1 billion in sales. However, six blockbuster products recorded sales declines, including three with double-digit drops. The company expects multiple drug candidates with recently positive late-stage clinical data to help fill those gaps.
Key facts
- U.S. new-to-brand prescriptions for Amgen's Repatha rose more than 60%, supported by increased use in secondary prevention and high-risk primary prevention patients. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | U.S. new-to-brand prescriptions for Amgen's Repatha rose more than 60%, supported by increased use in secondary prevention and high-risk… |